Home » Topics » Regulatory » EMA

EMA
RSS

EMA's CHMP recommends conditional approval of Lilly's olaratumab

Sep. 16, 2016

EMA validates Cempra's MAA for solithromycin

Aug. 24, 2016

COMP grants orphan drug designation to AB Science's masitinib in ALS

Aug. 9, 2016

EMA accepts for review MAA for sarilumab

Aug. 1, 2016

Adaptimmune Therapeutics gains access to EMA's PRIME initiative for T-cell therapy

July 29, 2016

Omeros receives scientific advice from EMA on phase III program for OMS-721

July 29, 2016

EMA grants PRIME designation to DNX-2401 for recurrent glioblastoma

July 28, 2016

Ebola Zaire vaccine wins FDA breakthrough therapy designation and PRIME status

July 26, 2016

EMA's CHMP adopts positive opinion on type II variation application for Gilead's Truvada

July 25, 2016

EMA committee supports approval of Eisai's Kisplyx

July 25, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...